By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


HPV vaccine indicated for treating anal cancers

The European Commission has approved the use of Gardasil – the quadrivalent human papillomavirus vaccine – for preventing anal precancerous lesions and anal cancers that are causally related to certain oncogenic HPV types in men and women.

It is already indicated for the prevention of HPV-related cervical cancer and premalignant genital lesions in females aged nine and over. 

The vaccine, which is manufactured by Sanofi Pasteur MSD, protects against HPV types 6, 11, 16, 18.

This new indication “acknowledges the efficacy of Gardasil, targeting the high-risk HPV types 16 and 18 which cause the vast majority of anal cancers”, said Sanofi in a statement.


Readers' comments (3)

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!